Puma Biotechnology, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q2 2024 | 1 | -$0.13 | -$0.13 | -$0.13 |
| Q3 2024 | 1 | $0.33 | $0.33 | $0.33 |
| Q4 2024 | 2 | $0.07 | $0.11 | $0.09 |
| Q1 2025 | 1 | $0.06 | $0.06 | $0.06 |
| Q2 2025 | 0 | $0.00 | $0.00 | $0.00 |
| Q3 2025 | 0 | $0.00 | $0.00 | $0.00 |
| Q4 2025 | 0 | $0.00 | $0.00 | $0.00 |
Puma Biotechnology, Inc. Earnings Date And Information
Puma Biotechnology, Inc. last posted its earnings results on Thursday, November 7th, 2024. The company reported $0.41 earnings per share for the quarter, topping analysts' consensus estimates of $0.35 by $0.06. The company had revenue of 56.14 M for the quarter and had revenue of 235.64 M for the year. Puma Biotechnology, Inc. has generated $0 earnings per share over the last year ($0.45 diluted earnings per share) and currently has a price-to-earnings ratio of 6.33. Puma Biotechnology, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based on prior year's report dates.
Puma Biotechnology, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/07/2024 | Q3 2024 | $0.35 | $0.41 | 0.06 | $70.65 M | $56.14 M |
| 08/01/2024 | Q2 2024 | -$0.10 | -$0.09 | 0.01 | $44.70 M | $47.08 M |
| 05/02/2024 | Q1 2024 | -$0.16 | -$0.10 | 0.06 | $43.77 M | |
| 02/29/2024 | Q4 2023 | $0.30 | $0.26 | -0.04 | $72.18 M | |
| 11/02/2023 | Q3 2023 | $0.08 | $0.12 | 0.04 | $57.95 M | $56.12 M |
| 08/03/2023 | Q2 2023 | $0.07 | $0.05 | -0.02 | $51.73 M | $54.57 M |
| 05/04/2023 | Q1 2023 | $0.04 | $0.03 | -0.01 | $52.78 M | |
| 03/02/2023 | Q4 2022 | $0.06 | -$0.12 | -0.18 | $65.70 M | |
| 11/03/2022 | Q3 2022 | -$0.11 | -$0.01 | 0.1 | $50.47 M | $57.10 M |
| 08/04/2022 | Q2 2022 | $0.00 | $0.21 | 0.21 | $52.62 M | $59.52 M |
| 05/05/2022 | Q1 2022 | -$0.13 | -$0.08 | 0.05 | $45.74 M | |
| 03/03/2022 | Q4 2021 | -$0.09 | $0.10 | 0.19 | $55.40 M | |
| 11/04/2021 | Q3 2021 | -$0.23 | -$1.09 | -0.86 | $53.33 M | $46.25 M |
| 08/05/2021 | Q2 2021 | -$0.31 | -$0.13 | 0.18 | $53.14 M | $53.38 M |
| 05/06/2021 | Q1 2021 | $0.09 | $0.41 | 0.32 | $98.17 M | |
| 03/01/2021 | Q4 2020 | -$0.38 | $52.60 M | |||
| 11/05/2020 | Q3 2020 | -$0.33 | -$0.79 | -0.46 | $52.97 M | $50.75 M |
| 08/06/2020 | Q2 2020 | -$0.30 | $0.09 | 0.39 | $57.61 M | $70.58 M |
| 05/07/2020 | Q1 2020 | -$0.79 | -$0.43 | 0.36 | $51.22 M | |
| 02/27/2020 | Q4 2019 | -$0.29 | $62.90 M |
Puma Biotechnology, Inc. Earnings: Frequently Asked Questions
-
When is Puma Biotechnology, Inc.'s earnings date?
Puma Biotechnology, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, February 27th, 2025 based off last year's report dates.
-
Did Puma Biotechnology, Inc. beat their earnings estimates last quarter?
In the previous quarter, Puma Biotechnology, Inc. (:PBYI) reported $0.41 earnings per share (EPS) to beat the analysts' consensus estimate of $0.35 by $0.06.
-
How can I listen to Puma Biotechnology, Inc.'s earnings conference call?
The conference call for Puma Biotechnology, Inc.'s latest earnings report can be listened to online.
-
How can I read Puma Biotechnology, Inc.'s conference call transcript?
The conference call transcript for Puma Biotechnology, Inc.'s latest earnings report can be read online.
-
How much revenue does Puma Biotechnology, Inc. generate each year?
Puma Biotechnology, Inc. (:PBYI) has a recorded annual revenue of $235.64 M.
-
How much profit does Puma Biotechnology, Inc. generate each year?
Puma Biotechnology, Inc. (:PBYI) has a recorded net income of $235.64 M. Puma Biotechnology, Inc. has generated $0.46 earnings per share over the last four quarters.
-
What is Puma Biotechnology, Inc.'s price-to-earnings ratio?
Puma Biotechnology, Inc. (:PBYI) has a price-to-earnings ratio of 6.33 and price/earnings-to-growth ratio is 0.04.
